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Effects of long-acting beta-2 agonist treatment on daily energy
balance and body composition in patients with chronic
obstructive pulmonary disease
Abdurrahman GENÇ1, Kağan ÜÇOK1, Ersin GÜNAY2, Yücel GÖNÜL3, Hatice KARABACAK1,
Ümit ŞENER1, Serkan NURAL2, Mehmet ÜNLÜ2

Aim: The aim of this study was to investigate the effects of long-acting beta-2 agonist (formoterol) treatment on the
resting metabolic rate (RMR), daily physical activity, body composition and anthropometry, nutritional status, and
quality of life of patients with chronic obstructive pulmonary disease (COPD).
Materials and methods: A total of 30 male patients who were diagnosed with COPD participated in the study. The
RMR was determined using an indirect calorimeter, daily physical activity was measured with an accelerometer, and
body composition was established by bioelectric impedance analysis. Body circumference and skinfold thickness
measurements were carried out. Pulmonary function tests were performed with a spirometer. The 36-item short-form
health survey (SF-36) quality of life questionnaire and dietary intake records were obtained from the participants.
Following the initial measurements, the patients received a 12-µg formoterol inhaler twice daily for 3 months. At the
end of the 3 months, all of the measurements and questionnaires were collected once again.
Results: Although the RMR, daily physical activity, body mass index, body fat percentage and fat distribution
measurements, dietary intake record, and quality of life questionnaire scores were not statistically different before and
after treatment in the patients with COPD, an increase in pulmonary function tests (forced expiratory volume in 1 s and
peak expiratory flow) was recorded.
Conclusion: Our results suggest that 3-month long-acting beta-2 agonist treatment does not change the daily energy
balance and body composition in male COPD patients.
Key words: Chronic obstructive pulmonary disease, beta-2 agonist, resting metabolic rate, daily physical activity, body
fat, anthropometry

Introduction
Chronic obstructive pulmonary disease (COPD) is a
major public health problem. Worldwide, COPD is in
the spotlight because its high prevalence, morbidity,
and mortality create formidable challenges for
healthcare systems (1). COPD is a severe disease
that leads to a nonreversible obstruction of the small
airways.

COPD is largely the result of smoking, and
the consequences of this habit generally become
clinically apparent during the late productive
period of life. Tobacco smoking represents the
most important risk factor for respiratory diseases
and it is the primary risk factor for COPD (2). Age
of starting smoking, total pack years smoked, and
current smoking status are all predictive of COPD
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mortality (3). Nevertheless, smoking cessation is
recognized as essential to the treatment of COPD. In
addition to smoking intervention, pharmacological
treatment remains a key to therapy for patients with
COPD (4).
COPD is known to be both pathophysiologically
and clinically heterogeneous, with highly variable
rates of progression (5). It appears that patients
with respiratory symptoms tend to have a more
accelerated progression of airflow obstruction, while
those who are asymptomatic are less likely to have
progressive disease (6). A functional assessment
is the use of subjective and objective data, often
from diagnostic tools, to obtain a description of an
individual’s functional status or ability to participate
in everyday activities by quantifying the effects of
the disease severity on physical and psychological
function (7). Dyspnea is a major contributor to
decreased exercise capacity and functional status
in this population (8). Moreover, body weight loss,
often observed in patients with COPD, is related to
a lack of appetite.
Formoterol is a rapidly acting, well-tolerated,
effective beta-2-adrenergic receptor agonist that can
be regularly used as a long-acting bronchodilator
for patients with moderate to severe COPD, as
per recommendations of the current treatment
guidelines (9). Inhaled formoterol reduces symptoms
and improves lung function and the general health
status in patients with COPD.
The COPD management program emphasizes
the importance of early detection and intervention
to prevent and reduce the long-term consequences
of disease progression (4). It is also essential
for physicians to understand and evaluate all of
the aspects of COPD patients, including their
physiological parameters.
The aims of this study were to investigate the effect
of long-acting beta-2 agonist treatment (formoterol
inhaler) on the resting metabolic rate (RMR), daily
physical activity, body fat percentage, lean body mass
and body fat distribution, nutritional status, and
quality of life of patients with COPD.

Materials and methods
Patients
The study protocol was approved by the local ethical
committee of clinical research, and all of the patients
participated voluntarily with written informed
consent. Inclusion criteria were as follows: patients
who were diagnosed with COPD and who planned
to receive formoterol. A total of 30 COPD patients,
between 43 and 67 years of age, were enrolled in the
study. Classification of disease severity was made
using the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) recommendations (10).
There was an indication for receiving long-acting
beta-2 agonist treatment in the COPD patients.
Exclusion criteria were as follows: asthma; atopy;
acute infection; metabolic, cardiovascular, or other
systemic diseases; and use of drugs affecting basal
metabolism. A total of 30 male patients who were
diagnosed with COPD participated in the study.
First, all of the measurements were taken and the
questionnaires were administered in the sports
physiology laboratory. Following the measurements,
the patients received a 12-µg formoterol inhaler twice
daily for 3 months. At the end of the 3 months, all of
the measurements and questionnaires were collected
once again.
Resting metabolic rate
RMR was measured using an indirect calorimeter
(Quark b2, Cosmed, Rome, Italy) with a computerized
metabolic card, which analyzed the oxygen
consumption and carbon dioxide production (11).
The device was calibrated prior to each test. The
subjects were instructed to avoid food intake for 12
h and to not perform exercise for 24 h before the test.
The tests were performed at the same time (0830–
1030 hours) of the day. After resting for 15 min, the
measurements were taken for all of the subjects in a
silent, lightless laboratory at room temperature. The
subjects were asked to put on a face mask, lie in a
supine position, and not move their arms or legs
during the test.
Daily physical activity
Daily physical activity was measured using an
accelerometer (RT3, Stayhealthy Inc., Monrovia,
CA,
USA).
The
accelerometer
measures
acceleration in each anatomical axis with vertical
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(x), anterioposterior (y), and mediolateral (z)
measurements. The accelerometer was attached to
a belt, using its integral belt clip, and worn on the
right hip of the patients. The epoch interval was set
at 1 min and output was expressed as mean counts
per minute for each activity (12). The accelerometer
periodically measures acceleration and converts it to
a digital representation, which is then processed to
obtain an ‘activity count’ that is stored in the memory.
Participants were monitored with an accelerometer
for 12 h (0800–2000 hours) per day for 3 days. The
mean value of the 3 days was calculated (kcal/12 h).
Body composition
The body fat and lean body mass of the patients were
determined using a bioelectrical impedance analysis
system (Bodystat 1500, Bodystat Ltd., Douglas, Isle of
Man, UK). Metal accessories (belts, cell phones, etc.)
were removed from the body (13). Heavy physical
exercise was restricted for 24 h before the test.
Impedance was measured between the right wrist
and right ankle using a tetrapolar electrode system.
The subjects lay supine, with the arms separated
from the body and the legs not touching each other.
Signal electrodes were positioned in the middle of
the dorsal surface of the hands and feet, proximal to
the metacarpophalangeal and metatarsophalangeal
joints. Detecting electrodes were more proximally
positioned at the ankle and the wrist. An excitation
current of 500 µA at 50 kHz was applied to the distal
electrodes, and the voltage was detected by proximal
electrodes. The data were analyzed using the
manufacturer’s software, and the body fat percentage,
total body fat, and lean body mass were determined
for each patient. Exclusion criteria were conditions
that change the body fluid–electrolyte balance, such
as dehydration.
Anthropometric measurements
Skinfold thickness measurements were taken using a
skinfold caliper (Holtain Ltd., Crosswell, Wales, UK).
The skin was picked up between the thumb and index
finger, and the caliper was applied about 1 cm from
the fingers (14). The measurements were either taken
in rotation through measurement sites or a period
of time was allowed for the skin to regain normal
texture and thickness. Standardized sites were used
for skinfold thickness measurements as follows
(15): biceps, triceps, subscapular, midaxillary, chest
1416

(pectoral), abdominal, suprailiac, thigh, and medial
calf skinfold.
Circumference measurements were taken at
standing-straight but relaxed positions with a
measuring tape. The tape was held parallel to the
ground and completely surrounded the part of the
body, but it did not compress the subcutaneous fat
tissue. Duplicate measurements were taken at each
site and retests were done if duplicate measurements
were not within 7 mm. The standardized sites used for
circumference measurements were as follows (15):
waist circumference was measured at the narrowest
part of the torso at the end of the expiration, hip
circumference was measured at the widest part
over the buttocks, and abdomen circumference
was measured horizontally at the level of greatest
anterior protuberance of the abdomen (usually at the
umbilicus) at the end of the expiration. The waist-tohip ratio was calculated.
Height was measured using an inflexible steel
meter while the subjects stood with heels, back,
and shoulders against a wall, with feet together
and head on the Frankfort plane (16). The body
weight measurements were taken with the subjects’
outerwear and shoes removed, using calibrated
measurement devices (17). Body mass index (BMI)
was calculated as the body weight divided by the
square of the height (kg/m2). The BMI is mostly used
as a reference parameter for the assessment of obesity
(18).
Pulmonary function tests
Pulmonary function tests were performed twice with
a spirometer (Quark b2, Cosmed). The tests were
performed at room temperature (19). Acceptability
criteria were applied to all of the participants (20).
The tests were explained to the patients prior to
each measurement and a test was performed for
adaptation. The procedure required the patient to
wear a nose clip and perform a forced expiratory
maneuver. Before the mouthpiece was placed into the
patient’s mouth, the patient was instructed to inhale
completely and then make as deep and rapid of an
expiration as possible. The forced expiratory volume
in 1 s (FEV1), forced vital capacity (FVC), forced
expiratory flow at 25%–75% vital capacity (FEF25–75),
and peak expiratory flow (PEF) were measured, and
the FEV1/FVC ratio was calculated.
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The maximal voluntary ventilation (MVV) was
measured using another spirometry maneuver. The
patient’s expired maximal volume during 12 s of
forced breathing into the spirometer was measured
and MVV was calculated for 1 min.

3 days. The participants recorded their dietary intake
on the form using the measurement of nutrients for
3 days (25). The calories of all of the nutrients were
calculated for each day. The mean value for a day was
determined from 3 days of data.

Short-form health survey (SF-36)

Statistical analysis

The SF-36 is a multipurpose health survey with only
36 questions. A validity and reliability study of the SF36 was conducted in Turkey (21). The SF-36 has been
useful in comparing general and specific populations,
comparing the relative burden of diseases, differentiating
the health benefits produced by a wide range of different
treatments, and screening individual patients (22). It
yields an 8-scale profile of scores, as well as physical and
mental health summary measures (23):

The data were analyzed using SPSS 18.0 (SPSS, Chicago,
IL, USA). All of the parametric results were expressed as
mean ± standard deviation for each group. Distribution
of the group was analyzed with the Kolmogorov–
Smirnov test. Differences between means were analyzed
with Student’s t-test or the Mann–Whitney U test
according to the distribution of the data. The significance
level was determined at P ≤ 0.05.

-Physical health: physical functioning, role–
physical, bodily pain, and general health.

Results

-Mental health: vitality, social functioning, role–
emotional, and mental health.
Responses from the SF-36 are summed and then
transformed to give 8 scores with a 0–100 scale,
where higher scores indicate better functioning in
that dimension (24).
Dietary intake record
The record form is a newly developed estimated
dietary record form for use in home settings and
is designed to be self-explanatory. The record form
includes all meals, snacks between meals, and a list
of measures of nutrients (e.g., number, slice, a soap
plate, a tablespoon, a dessert spoon, a water glass) for

The mean age of the COPD patients was 57.9 ± 10.2
years. The mean values of the RMR, daily physical
activity, dietary intake record, and body composition
values before and after treatment are shown in Table
1. There was no significant difference in the RMR,
daily physical activity, dietary intake record, and
body composition values before and after treatment.
The mean height of the COPD patients was
169.4 ± 6.6 cm. Table 2 shows the body weight,
BMI, circumference measurements, and waist-tohip ratio values in patients with COPD. There was
no significant difference in the body weight, BMI,
circumference measurements, and waist-to-hip ratio
values before and after treatment.

Table 1. RMR, daily physical activity, dietary intake records, and body composition values before and
after treatment.
Before treatment
(n = 30)

After treatment
(n = 30)

P-value

RMR (kcal/day)

1881.0 ± 430.0

1806.3 ± 483.2

0.621

Physical activity (kcal/12 h)

628.4 ± 238.9

640.3 ± 264.6

0.896

Dietary intake (kcal/day)

2496.8 ± 570.5

2507.4 ± 658.4

0.952

Body fat (%)

29.2 ± 6.2

30.0 ± 7.1

0.876

Total body fat (kg)

23.5 ± 6.5

24.1 ± 7.7

0.954

Lean body mass (kg)

56.2 ± 8.7

55.8 ± 8.2

0.795

RMR: Resting metabolic rate.

1417

Effects of formoterol on energy balance in COPD

Table 2. Body weight, BMI, waist-to-hip ratio, and circumference measurement values before and after
treatment.
Before treatment
(n = 30)

After treatment
(n = 30)

P-value

Body weight (kg)

79.6 ± 12.5

79.8 ± 11.9

0.839

BMI (kg/m2)

27.9 ± 3.6

28.0 ± 3.7

0.628

Waist circumference (cm)

93.9 ± 8.1

94.7 ± 8.6

0.764

Abdomen circumference (cm)

99.4 ± 9.2

99.6 ± 9.6

0.945

Hip circumference (cm)

97.4 ± 6.8

97.6 ± 7.1

0.929

Waist-to-hip ratio

0.96 ± 0.06

0.97 ± 0.06

0.738

BMI: Body mass index

Table 3 lists the skinfold measurement values
before and after treatment in patients with COPD.
There was no significant difference in the skinfold
measurement values before and after treatment. The
skinfold and circumference measurements and the
waist-to-hip ratio reflect the body fat distribution
(e.g., central obesity, upper or lower body fatness) in
the patients.
The mean values of the pulmonary function tests
and smoking before and after treatment in patients

with COPD are shown in Table 4. We found that the
FEV1 and PEF values were significantly higher after
treatment than before treatment in patients with
COPD. There were no significant differences in the
other pulmonary function tests and smoking values
before and after treatment.
Table 5 shows the quality of life questionnaire (SF36) scores before and after treatment in patients with
COPD. There was no significant difference in the SF36 scores before and after treatment.

Table 3. Skinfold measurement values before and after treatment.
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Before treatment
(n = 30)

After treatment
(n = 30)

P-value

Triceps (mm)

12.7 ± 4.8

12.3 ± 4.1

0.779

Biceps (mm)

6.1 ± 2.1

6.6 ± 1.9

0.459

Subscapular (mm)

18.1 ± 4.5

18.8 ± 5.1

0.635

Midaxillary (mm)

16.1 ± 5.1

17.1 ± 5.0

0.542

Pectoral (chest) (mm)

18.0 ± 5.7

18.5 ± 5.6

0.761

Abdominal (mm)

29.8 ± 9.2

30.9 ± 8.9

0.702

Suprailiac (mm)

16.9 ± 6.8

16.6 ± 6.5

0.879

Thigh (mm)

16.1 ± 5.9

16.3 ± 6.0

0.923

Medial calf (mm)

11.7 ± 3.8

11.9 ± 4.0

0.834
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Table 4. Pulmonary function test results and cigarette consumption before and after treatment.
Before treatment
(n = 30)

After treatment
(n = 30)

P-value

FVC (L)

3.4 ± 0.9

3.7 ± 0.9

0.196

FEV1 (L)

2.3 ± 0.6

2.7 ± 0.6

0.041

FEV1/FVC (%)

67.3 ± 7.7

70.6 ± 8.1

0.111

PEF (L)

4.9 ± 1.6

6.2 ± 1.9

0.035

FEF25–75 (L)

1.6 ± 0.6

1.9 ± 0.6

0.066

MVV (L)

91.5 ± 31.4

102.1 ± 32.9

0.204

Smoking (pack-years)

43.0 ± 20.3

43.0 ± 20.3

1.000

FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 second), PEF (peak expiratory flow),
FEF25-75 (forced expiratory flow at 25% to 75% vital capacity), MVV (maximal voluntary ventilation)
Table 5. Quality of life questionnaire (SF-36) scores before and after treatment.
Before treatment
(n = 30)

After treatment
(n = 30)

P-value

Physical health score

81.5 ± 13.5

85.3 ± 10.2

0.321

PF score

85.5 ± 15.9

89.7 ± 17.2

0.342

RP score

88.7 ± 17.2

88.8 ± 15.5

0.990

BP score

77.3 ± 20.8

85.2 ± 19.5

0.229

GH score

76.2 ± 19.0

79.2 ± 15.5

0.599

Mental health score

89.1 ± 6.7

90.5 ± 7.9

0.536

VT score

81.8 ± 9.9

85.8 ± 10.3

0.241

SF score

96.0 ± 8.8

96.8 ± 8.2

0.760

RE score

96.6 ± 0.5

94.7 ± 12.4

0.578

MH score

91.0 ± 8.2

91.4 ± 8.6

0.881

Total score

83.9 ± 9.5

86.9 ± 7.5

0.288

PF: physical functioning, RP: role–physical, BP: bodily pain, GH: general health, VT: vitality, SF: social
functioning, RE: role–emotional, MH: mental health.

Discussion
COPD is defined as a preventable and treatable
disease characterized by airflow limitation that is
not fully reversible (4). With regard to respiratory
function, it must be pointed out that smokers are
at a higher risk of decreased FEV1, with an excess
annual FEV1 decline ranging from 7 mL/year to
33 mL/year (26). Chhabra et al. (27) applied single

doses of formoterol (12 µg) to 44 stable patients with
COPD and found that the formoterol resulted in an
immediate improvement in lung function. Aalbers et
al. (28) treated 692 COPD patients with formoterol
(4.5, 9, or 18 µg, 2 times a day) or a placebo via
Turbuhaler for 12 weeks. They found that the FEV1
improved significantly after all 3 doses of formoterol.
Similar to these studies, we found that the pulmonary
functions (FEV1 and PEF) increased significantly
1419
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after 3 months of formoterol treatment (Table 4). The
bronchodilatory effect of long-acting beta-2 agonists
seemed to be fairly stable after regular treatment with
bronchodilators in patients with COPD (29).
Bronchodilators could have 2 opposite effects
on energy expenditure in patients with airway
obstruction: first, an increase in energy expenditure
due to a direct thermogenic effect, and second, a
decrease in energy expenditure due to diminished
work of breathing because of bronchodilation (30).
In this study, we found that there was no significant
difference in RMR, daily physical activity, or dietary
intake before and after treatment (Table 1). Cazzola
et al. (31) found that formoterol was not able to
reduce energy expenditure during 6-min walking
tests in COPD patients. They hypothesized that
the reduction in pulmonary hyperinflation was not
enough to induce a reduction in energy expenditure.
Moreover, it is well known that continuous longterm exposure to beta adrenergic agonists results in
the downregulation of mRNA and receptor protein
with the rapid onset of tolerance to their effects (32).
Therefore, the thermogenic effect of formoterol
would be expected to be transient in nature and it is
likely that the regular use of this drug does not affect
the energy expenditure in COPD patients (31).
Patients with COPD often have limited daily
physical activity. However, the level, type, and
intensity of daily physical activity are not known,
nor is there clear insight into the contributing factors
(33). Dyspnea leads to inactivity, which leads to
physical deconditioning, and a vicious circle ensues.
It was found that using inhaled formoterol is effective
in ameliorating exercise intolerance in patients with
COPD (34–36). However, Aalbers et al. (28) found
no differences between groups using formoterol and
a placebo in walking distance in a shuttle walking test.
Moreover, Wadbo et al. (37) found that formoterol
improved the airway function and symptoms, without
significant improvements in the shuttle walking test
and quality of life. In the current study, it was found
that there was no significant difference in the daily
physical activity before and after treatment (Table 1).
A study using the SF-36 reported that the physical
subscale of the health status questionnaire was
positively correlated with daily physical activity (r =
0.40, P < 0.001), whereas correlation with the mental
1420

subscale was not (r = 0.15, not significant) (38).
Regular treatment of patients with COPD with longacting beta-2 agonists can induce an improvement in
the respiratory function and certain aspects of quality
of life (29). We found that there was no significant
difference in the SF-36 scores and smoking (pack
year) values before and after treatment (Tables 4 and
5). The lack of effect on quality of life of the treatment
might at least partially be explained by the severity of
COPD, with little or no reversibility in these patients
(37). We believe that because of active cigarette
smoking and the progressive characteristic of COPD,
daily physical activity and quality of life were not
significantly improved with long-acting beta-2
agonist treatment in patients with COPD. Smoking
cessation is the mainstay of the management of
COPD because it reduces the decline in pulmonary
function, improves the prognosis, and enhances
quality of life (39,40).
Malnutrition is a common and often
underrecognized problem in patients with COPD.
Malnutrition in COPD, with the increased secretion
of inflammatory mediators, the increased metabolic
rate due to the ventilatory effort, and the therapeutic
use of sympathomimetic drugs, together with a lack
of appetite that results in decreased caloric intake
and weight loss, is multifactorial (41). BMI has
been shown to be a predictor of functional ability
in people with COPD and a reduction in BMI
adversely affects the clinical outcomes in COPD (8).
With the development of COPD, peripheral muscles
may undergo compositional changes with a loss of
peripheral muscle mass, despite the patient having
a normal BMI (7). Peripheral muscle composition
is recognized as an important factor in assessing
functional ability and exercise capacity. We measured
the lean body mass, which includes the body muscle
mass, of the patients. The present study demonstrates
that there was no significant difference in the BMI,
body composition (body fat %, total body fat, and
lean body mass), and body fat distribution (skinfold
and circumference measurements and waist-tohip ratio) values before and after treatment in
patients with COPD. Because of the energy balance
between the energy intake and expenditure, the body
composition and body fat distribution parameters
may not be changed with long-acting beta-2 agonist
treatment in patients with COPD.
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In conclusion, our results suggest that long-acting
beta-2 agonist (formoterol) treatment does not
change the daily energy balance parameters, which

are RMR, daily physical activity, and dietary intake,
as well as body composition parameters such as body
fat and lean body mass in male COPD patients.
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